Universities and Businesses Collaborate to Revolutionize Cardiovascular Disease Diagnosis

Heart Test Laboratories (HeartSciences) and the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) have recently entered into license agreements to advance the development and commercialization of artificial intelligence (AI) algorithms and assets for electrocardiography (ECG), revolutionizing the diagnosis of cardiovascular disease.

These groundbreaking licenses not only solidify the partnership between HeartSciences and Icahn Mount Sinai but also make Icahn Mount Sinai a shareholder in HeartSciences. The licenses grant Icahn Mount Sinai the right to utilize a range of patented and unpatented AI-powered ECG algorithms and technologies for the screening and diagnosis of cardiovascular disease.

With these licenses in place, HeartSciences gains access to a comprehensive collection of AI-driven ECG algorithms. Through their cloud-based, hardware-agnostic platform, HeartSciences plans to leverage these algorithms and make them available for use with multiple ECG devices from around the world, including their innovative MyoVista device.

The development of these advanced algorithms was made possible through a meticulous analysis of a vast database of ECG records. Faculty members from Icahn Mount Sinai have played a pivotal role in the development of this groundbreaking technology, which has now been licensed to HeartSciences.

Through this collaboration, HeartSciences and Icahn Mount Sinai seek to transform the field of cardiovascular disease diagnosis, offering healthcare professionals access to cutting-edge AI algorithms that will improve diagnostic accuracy and patient care.

FAQ:

What is electrocardiography (ECG)?

Electrocardiography, or ECG, is a medical test that records the electrical activity of the heart. It is commonly used to detect and diagnose heart conditions.

How does artificial intelligence (AI) enhance ECG analysis?

Artificial intelligence can analyze large amounts of data from ECG readings and identify patterns or abnormalities that may go unnoticed by human doctors. AI algorithms can improve the accuracy and speed of diagnosis, leading to more effective treatment and better patient outcomes.

What is the MyoVista device?

The MyoVista device is an innovative ECG device developed by HeartSciences. It is designed to provide advanced cardiac testing capabilities and is compatible with AI algorithms for improved diagnosis of cardiovascular disease.

(Source: Company Press Release)